EUR 0.08
(-1.89%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -4.79 Million EUR | -39.86% |
2022 | -2.76 Million EUR | -315.58% |
2021 | -719 Thousand EUR | 13.37% |
2020 | -1.31 Million EUR | 46.35% |
2019 | -1.54 Million EUR | 51.17% |
2018 | -3.16 Million EUR | -3005.88% |
2017 | -102 Thousand EUR | 93.12% |
2016 | -1.48 Million EUR | -44.05% |
2015 | -1.32 Million EUR | 14.25% |
2014 | -1.26 Million EUR | -788.37% |
2013 | 200.05 Thousand EUR | -62.53% |
2012 | 533.68 Thousand EUR | 22.59% |
2011 | 379.66 Thousand EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -854 Thousand EUR | 0.0% |
2023 Q4 | -2.29 Million EUR | 0.0% |
2023 Q2 | -488 Thousand EUR | 0.0% |
2023 FY | - EUR | -39.86% |
2022 Q2 | -615 Thousand EUR | 0.0% |
2022 FY | - EUR | -315.58% |
2022 Q4 | -1.9 Million EUR | 0.0% |
2021 FY | - EUR | 13.37% |
2021 Q2 | -229 Thousand EUR | 0.0% |
2021 Q4 | -490 Thousand EUR | 0.0% |
2020 Q4 | -110 Thousand EUR | 0.0% |
2020 FY | - EUR | 46.35% |
2020 Q2 | -775 Thousand EUR | 0.0% |
2019 Q2 | -1.16 Million EUR | 0.0% |
2019 Q4 | 837 Thousand EUR | 0.0% |
2019 FY | - EUR | 51.17% |
2018 Q2 | -590 Thousand EUR | 0.0% |
2018 FY | - EUR | -3005.88% |
2018 Q4 | -2.57 Million EUR | 0.0% |
2017 Q2 | 1.14 Million EUR | 0.0% |
2017 FY | - EUR | 93.12% |
2017 Q4 | -1.24 Million EUR | 0.0% |
2016 Q2 | -274 Thousand EUR | 0.0% |
2016 FY | - EUR | -44.05% |
2016 Q4 | -1.2 Million EUR | 0.0% |
2015 FY | - EUR | 14.25% |
2015 Q4 | -378.36 Thousand EUR | 0.0% |
2015 Q2 | -651.1 Thousand EUR | 0.0% |
2014 Q4 | -716.28 Thousand EUR | 0.0% |
2014 Q2 | -484.2 Thousand EUR | 0.0% |
2014 FY | - EUR | -788.37% |
2013 FY | - EUR | -62.53% |
2013 Q4 | 320.07 Thousand EUR | 0.0% |
2013 Q2 | -145.68 Thousand EUR | 0.0% |
2012 Q1 | 117.6 Thousand EUR | 0.0% |
2012 Q2 | 117.6 Thousand EUR | 0.0% |
2012 Q3 | 117.6 Thousand EUR | 0.0% |
2012 Q4 | 18.6 Thousand EUR | -84.18% |
2012 FY | - EUR | 22.59% |
2011 Q3 | 78.76 Thousand EUR | 0.0% |
2011 Q4 | 117.6 Thousand EUR | 49.31% |
2011 FY | - EUR | 0.0% |
2011 Q1 | 78.76 Thousand EUR | 0.0% |
2011 Q2 | 78.76 Thousand EUR | 0.0% |
2010 Q4 | 78.76 Thousand EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Crossject Société Anonyme | -7.29 Million EUR | 34.334% |
Safe Orthopaedics SA | -5.62 Million EUR | 14.812% |
Amplitude Surgical SA | 24.72 Million EUR | 119.375% |
Sartorius Stedim Biotech S.A. | 777.2 Million EUR | 100.616% |
EssilorLuxottica Société anonyme | 6.18 Billion EUR | 100.078% |
bonyf N.V. | -39.89 Thousand EUR | -11909.298% |